NCT06465745招募中不适用
ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation) Pivotal Trial
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 450
- 试验地点
- 67
- 主要终点
- Composite of all-cause mortality or heart failure hospitalization.
研究概览
简要总结
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Symptomatic New York Heart Association (NYHA) class II-IV.
- •Moderate-to-severe or severe MR (3+) despite optimal guideline-directed medical therapy (GDMT) as determined by an independent Echo Core Lab.
- •Unsuitable for surgery and Transcatheter Edge-toEdge Repair (TEER) as determined by the local site Heart Team.
排除标准
- •(Abbreviated List):
- •Inability to understand the trial or a history of non-compliance with medical advice.
- •Inability to provide signed Informed Consent Form (ICF).
- •History of any cognitive or mental health status that would interfere with participation in the trial.
- •Currently enrolled in any other pre-approval investigational trial (does not apply to long-term post-market trials unless these trials might clinically interfere with the current trial endpoints (e.g., limit use of trial-required medication, etc.)).
- •Female subjects who are pregnant or planning to become pregnant within the trial period.
- •Known hypersensitivity or contraindication to heparin, or warfarin without adequate alternative medications.
- •Known hypersensitivity to nitinol (i.e., nickel allergy) that cannot be adequately medicated.
- •Known hypersensitivity to contrast media that cannot be adequately medicated.
- •Evidence of current left ventricular ejection fraction (LVEF) ≤ 25%.
- •Concurrent medical condition with a life expectancy of less than 12 months.
- •Transcatheter aortic repair or replacement within 90 days prior to the baseline required tests.
- •Percutaneous coronary intervention (PCI) within 30 days prior to the index procedure.
研究组 & 干预措施
Primary Cohort
Experimental
Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population without at least moderate mitral annular calcification (MAC).
干预措施: AltaValve System. (Device)
Mitral Annular Calcification Cohort (MAC)
Experimental
Designed to evaluate the safety and performance of the AltaValve System for the treatment of moderate-to-severe or severe MR in a targeted patient population with moderate to severe MAC.
干预措施: AltaValve System. (Device)
结局指标
主要结局
Composite of all-cause mortality or heart failure hospitalization.
时间窗: 12 months.
次要结局
- Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ).(6 months and 1 year.)
- All-cause mortality, disabling stroke, acute kidney injury (stage 3 or with renal replacement), mitral valve re-intervention (surgical or transcatheter), major bleeding requiring intervention.(30 Days or hospital discharge (whichever is longer).)
- Technical success.(Day 0.)
- Mitral valve re-intervention.(At 30 days, 6 months, 1 year, and annually thereafter for up to 5 years.)
- Changes in Six-minute walk test (6MWT).(6 months and 1 year.)
- New pacemaker rate.(1 month, 6 months and 1 year.)
研究者
研究点 (67)
Loading locations...
相似试验
Unknown
不适用
AltaValve Early Feasibility Study ProtocolMitral InsufficiencyMitral Valve IncompetenceMitral Valve RegurgitationMitral IncompetenceMitral RegurgitationNCT039973054C Medical Technologies, Inc.15
已完成
不适用
Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary LesionsCoronary Artery DiseaseNCT01092416Abbott Medical Devices443
已完成
不适用
Pivotal, Single-arm Clinical Trial to Assess the Efficacy and Safety of the MedHub AutocathFFR Software DeviceNSTEMIStable AnginaUnstable AnginaNCT04861519Medhub Ltd.308
招募中
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of IBS Angel in Patients With Pulmonary Artery StenosisPulmonary Artery StenosisNCT04973540Biotyx Medical (Shenzhen) Co., Ltd.82
Unknown
不适用
Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaGlaucomaNCT03639870Glaukos Corporation65